The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
p53 protein accumulation and gene mutations in human glioma cell lines
Abstract
Mutations in, and aberrant expression of, the p53 tumor suppressor gene were assessed in 17 cell lines derived from human malignant brain tumors (glioblastoma multiforme). Ex‐ons 5 through 8 were screened by single strand conformational polymorphism analysis (SSCP), followed by direct DNA sequencing. Mutations were found in 6 of 17 glioma cell lines, i.e., at a frequency similar to that found in primary malignant gliomas. Loss of the wild type allele was observed in 4 of the mutated cell lines. Two cell lines had the same mutation (CGG → TGG; Arg → Trp) in codon 248. Five of 6 mutations were transitions, 4 of which occurred at CpG dinucleotides. In one cell line a 10‐bp deletion at the intron 4/exon 5 junction was found. Five of 6 glioma cell lines contained a mutation identical to that in the respective primary tumor despite prolonged in vitro culture (140‐221 passages). Thus, the acquisition of p53 mutations during culture appears to be infrequent. Two cell lines derived from heterozygous tumors maintained the wild type p53 allele during long term culture. p53 protein levels were assessed by immunofluorescence cytochemistry and immunoprecipitation followed by Western blot analysis and revealed elevated levels of the p53 protein, although to a variable extent, in all cell lines with p53 mutations. A marked p53 protein accumulation was also observed in two cell lines lacking p53 mutations in exons 5 through 8, indicating that a prolonged half life of the gene product is not solely dependent on an aberrant coding sequence. The remaining cell lines had either low levels or no detectable p53 protein; one of the latter contained a gross rearrangement of the p53 gene. Our results suggest that with respect to p53 gene status, glioma cell lines usually resemble the original tumors and may, therefore, be suitable for studying the biological changes associated with p53 mutations in glial tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The absence of detected p53 protein in BT216 can be explained by the fact that deletion mutations resulting in truncated protein do not lead to detectable protein accumulation [23, 24].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [23]
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 2×
“Three mutations were located at the previously identified hot spots, codons 248 and 273 (Hollstein et al., 1991).”
BackgroundLane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 2×
“It has been proposed (Lane, 1992; Vogelstein and Kinzler, 1992) that the function of p53 is to prevent cells with damaged DNA from dividing until the damage is repaired.”
BackgroundGerm Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · cited 1×
“Mutations of the p53 tumor suppressor gene have been identified in a wide variety of human neoplasms (Hollstein et al., 1991), including the Li-Fraumeni syndrome hereditary tumors (Malkin et al., 1990).”
BackgroundOrita, M., Suzuki, Y., Sekiya, T., & Hayashi, K. (1989) · Genomics · doi:10.1016/0888-7543(89)90129-8 · Cited by 3,434 · cited 1×
“PCR-SSCP and direct DNA sequencing PCR-SSCP analysis was essentially performed as described by Orita et al. (1989).”
MethodMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 1×
“The p53 protein can be inactivated by mutation or by forming complexes with oncoproteins of DNA tumor viruses (Linzer and Levine, 1979; Werness ef al., 1990) or with the cellular protein mdm2 (Momand et al., 1992).”
BackgroundMutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862 · cited 4×
“The p53 gene encodes a nuclear 53 kDa phosphoprotein which acts as a transcriptional regulator by forming tetramers which bind to specific DNA sequences and exert a negative regulation of cell proliferation (reviewed by Vogelstein and Kinzler, 1992).”
BackgroundInfluentialLinzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813 · cited 1×
“The p53 protein can be inactivated by mutation or by forming complexes with oncoproteins of DNA tumor viruses (Linzer and Levine, 1979; Werness ef al., 1990) or with the cellular protein mdm2 (Momand et al., 1992).”
BackgroundMolecular basis of base substitution hotspots in Escherichia coli
Coulondre, C., Miller, J. H., Farabaugh, P. J., & Gilbert, W. (1978) · Nature · doi:10.1038/274775a0 · Cited by 1,193 · cited 1×
“The mechanism leading to this base exchange is thought to involve spontaneous hydrolytic deamination of 5-methylcytosine to thymine (Coulondre et aL, 1978), which results in a C -+ T transitiop.”
Background
Cited by
Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A., & Van Meir, E. G. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00536.x · Cited by 569
“Alternatively, mutation of TP53gene could occur in culture, but this is an uncommon event (2,39).”
BackgroundMetellus, P., Coulibaly, B., Colin, C., de Paula, A. M., Vasiljevic, A., Taieb, D., Barlier, A., Boisselier, B., Mokhtari, K., Wang, X. W., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0777-8 · Cited by 289
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., Steck, P. A., Roth, J. A., McDonnell, T. J., Steck, K. D., Levin, V. A., & Yung, W. K. A. (1996) · PubMed · Cited by 228
The p53 gene and its role in human brain tumors
Bögler, O., Su Huang, H. ‐., Kleihues, P., & Cavenee, W. K. (1995) · Glia · doi:10.1002/glia.440150311 · Cited by 187
Self-citationExpression of the neural RNA‐binding protein Musashi1 in human gliomas
Toda, M., Iizuka, Y., Yu, W., Imai, T., Ikeda, E., Yoshida, K., Kawase, T., Kawakami, Y., Okano, H., & Uyemura, K. (2001) · Glia · doi:10.1002/glia.1034 · Cited by 162
Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.
Chi, D. D., Merchant, R. E., Rand, R., Conrad, A. J., Garrison, D., Turner, R. R., Morton, D. L., & Hoon, D. S. �. (1997) · Europe PMC (PubMed Central) · Cited by 146
Hypoxia can induce c‐Met expression in glioma cells and enhance SF/HGF‐induced cell migration
Eckerich, C., Zapf, S., Fillbrandt, R., Loges, S., Westphal, M., & Lamszus, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22679 · Cited by 139
“TP53 mutations were analyzed as described previously, and results were compiled from Anker et al. (1993),23 Ishii et al. (1999)24 and Kim et al. (2005).25 Immunohistochemistry for p53 was performed on paraffin sections of human glioblastomas using a mouse monoclonal antibody againt p53 (clone DO-7,…”
MethodSelf-citationCharacterization of p53 and p21 Functional Interactions in Glioma Cells en Route to Apoptosis
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., Steck, P. A., Levin, V. A., Yung, W. K. A., & McDonnell, T. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.14.1036 · Cited by 142
“It is interesting that the incidence of p53 mutations in glioma cell lines is similar to that reported for primary brain tumors, indicating that these cell lines are useful tools for investigating the antineoplastic role of the wild-type p53 gene in gliomas ( 17 ).”
ResultYamamoto, T., Terada, N., Seiyama, A., Nishizawa, Y., Akedo, H., & Kosaka, H. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980105)75:1<81::aid-ijc13>3.0.co;2-g · Cited by 21
Self-citationA Correlative Study of p53 Protein Alteration and p53 Gene Mutation in Glioblastoma Multiforme
Newcomb, E. W., Madonia, W. J., Pisharody, S., Lang, F. F., Koslow, M., & Miller, D. C. (1993) · Brain Pathology · doi:10.1111/j.1750-3639.1993.tb00749.x · Cited by 118
Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
“The absence of detected p53 protein in BT216 can be explained by the fact that deletion mutations resulting in truncated protein do not lead to detectable protein accumulation (23, 24).”
BackgroundShu, H. G., Kim, M. M., Chen, P., Furman, F., Julin, C. M., & Israel, M. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14453 · Cited by 126
Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to Temozolomide
Wang, X., Chen, J., Liu, J., You, C., Liu, Y., & Mao, Q. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3380-0 · Cited by 106
Effect ofmts1 (S100A4) expression on the progression of human breast cancer cells
Grigorian, M., Ambartsumian, N. S., Lykkesfeldt, A. E., Bastholm, L., Elling, F., Georgiev, G. P., & Lukanidin, E. M. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960917)67:6<816::aid-ijc10>3.0.co;2-# · Cited by 108
Self-citationInfluence of p53 mutations on prognosis of patients with glioblastoma
Shiraishi, S., Tada, K., Nakamura, H., Makino, K., Kochi, M., Saya, H., Kuratsu, J., & Ushio, Y. (2002) · Cancer · doi:10.1002/cncr.10677 · Cited by 94
(2002) · PubMed · Cited by 85
Self-citationIL‐1β microenvironment promotes proliferation, migration, and invasion of human glioma cells
Fathima, K., Ramaswamy, P., & Nanjaiah, N. D. (2014) · Cell Biology International · doi:10.1002/cbin.10353 · Cited by 81
“With respect to p53 gene status, glioma cell lines resemble the original tumors and therefore are suitable for studying the biological changes associated with p53 mutations in glial tumors (Anker et al., 1993).”
BackgroundO6-Methylguanine-DNA Methyltransferase Regulation by p53 in Astrocytic Cells
Blough, M. D., Ƶlatescu, M. C., & Cairncross, J. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2782 · Cited by 85
“, found that glioblastomas harboring mutant p53 expressed lower levels of MGMT than tumors containing wildtype p53 (25).”
BackgroundRubner, Y., Muth, C., Strnad, A. R., Derer, A., Sieber, R., Buslei, R., Frey, B., Fietkau, R., & Gaipl, U. S. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-89 · Cited by 76
“The incidence of p53 mutations in glioma cell lines is similar to the primary tumor [22].”
BackgroundGorospe, M., Shack, S., Guyton, K. Z., Samid, D., & Holbrook, N. J. (1996) · PubMed · Cited by 57
Activation of NMDA receptor of glutamate influences MMP-2 activity and proliferation of glioma cells
Ramaswamy, P., Devi, N. A., Fathima, K., & Nanjaiah, N. D. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1604-5 · Cited by 57
Differential expression of novH and CTGF in human glioma cell lines
Xin, L. W., Martinerie, C., Zumkeller, W., Westphal, M., & Perbal, B. (1996) · Molecular Pathology · doi:10.1136/mp.49.2.m91 · Cited by 53
Self-citationDorigo, O., Turla, S. T., Lebedeva, S., & Gjerset, R. A. (1998) · Journal of neurosurgery · doi:10.3171/jns.1998.88.3.0535 · Cited by 54
Kim, E. L., Gunther, W. C., Yoshizato, K., Meissner, H., Zapf, S., Nüsing, R. M., Yamamoto, H., Meir, E. G. V., Deppert, W., & Giese, A. (2003) · Oncogene · doi:10.1038/sj.onc.1207155 · Cited by 51
“The human glioblastoma-derived cell lines (NCE-G22, G44, G59, G84, G112, G120, G123, G130, G168) (Anker et al., 1993) were propagated in MEM with 10% FCS (Biochem, Berlin, Germany), the glioma cell line SNB19 and the SNB19derived clone SNB19/B3 (SNB19 TR/TO/ets-1-B3, Yamamoto et al., 2000), the…”
BackgroundMethodKim, E. L., Rohaly, G., Heinrichs, S., Gimnopoulos, D., Meissner, H., & Deppert, W. (1999) · Oncogene · doi:10.1038/sj.onc.1203139 · Cited by 56
“G-130 is a human glioblastoma cell line which does not express p53 due to gross rearrangements within the p53 gene (Anker et al., 1993).”
Background1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth
Gozé, C., Bezzina, C., Gozé, É., Rigau, V., Maudelondé, T., Bauchet, L., & Duffau, H. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0831-6 · Cited by 49
Tumor Suppressor p53 Mediates Apoptotic Cell Death Triggered by Cyclosporin A
Pyrzyńska, B., Serrano, M., Martínez‐A, C., & Kaminska, B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104443200 · Cited by 50
Cordier, D., Gozé, C., Schädelin, S., Rigau, V., Mariani, L., & Duffau, H. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1623-y · Cited by 47
Somatostatin and somatostatin receptors in the diagnosis and treatment of gliomas
Lamszus, K., Meyerhof, W., & Westphal, M. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005893223090 · Cited by 45
“We therefore investigated SSTR gene expression, as well as the receptor content and function of a panel of 20 human glioblastoma derived cell lines, which have previously been shown to reflect many of the characteristics of the tumors from which they were derived [29, 30].”
Self-citationAntisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma
Julien, T. D., Frankel, B. M., Longo, S. L., Kyle, M. M., Gibson, S. A., Shillitoe, E. J., & Ryken, T. C. (2000) · Surgical Neurology · doi:10.1016/s0090-3019(00)00178-6 · Cited by 38
Khalid, M. H., Shibata, S., & Hiura, T. (1999) · Journal of neurosurgery · doi:10.3171/jns.1999.90.5.0918 · Cited by 37
Overexpression of bax in human glioma cell lines
Vogelbaum, M. A., Tong, J. X., Perugu, R., Gutmann, D. H., & Rich, K. M. (1999) · Journal of neurosurgery · doi:10.3171/jns.1999.91.3.0483 · Cited by 35
DNA ligase IV as a new molecular target for temozolomide
Kondo, N., Takahashi, A., Mori, E., Ohnishi, K., McKinnon, P. J., Sakaki, T., Nakase, H., & Ohnishi, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.045 · Cited by 35
“In newly diagnosed glioblastomas, MGMT sometimes shows low levels of activity! partly! because p53 mutations suppress MGMT expression [32–34] or MGMT promoter hypermethylation results in gene silencing of MGMT [35].”
BackgroundFigarella‐Branger, D., de Paula, A. M., Colin, C., & Bouvier, C. (2011) · Revue Neurologique · doi:10.1016/j.neurol.2011.07.006 · Cited by 33
Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells
Hietanen, S., Kurvinen, K., Syrjänen, K. J., Grénman, S., Carey, T. E., McClatchey, K. D., & Syrjänen, S. (1995) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(95)90636-3 · Cited by 26
Cressey, R., Pimpa, S., Tontrong, W., Wattananupong, O., & Leartprasertsuke, N. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.03.023 · Cited by 24
“The product of mutant p53 is frequently found to be metabolically stable protein with a long half-life [14,15].”
BackgroundAbsence of p53 autoantibodies in sera from glioma patients.
Rainov, N. G., Dobberstein, K.-U., Fittkau, M., Bahn, H., Holzhausen, H. ‐., Gantchev, L. S., & Burkert, W. L. (1995) · PubMed · Cited by 23
p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas
Gaiser, T., Becker, M. R., Meyer, J., Habel, A., & Siegelin, M. D. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.01.016 · Cited by 21
Apoptosis and proliferation: correlation with p53 in astrocytic tumours
Sarkar, C., Karak, A. K., Nath, N., Sharma, M. C., Mahapatra, A. K., Chattopadhyay, P., & Sinha, S. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-3015-1 · Cited by 21
“Glioma cells with p53 mutation have increased level of this protein which could also be present in the cytoplasm [62].”
Reis, R. M., Herva, R., Brandner, S., Koivukangas, J. P., Mironov, N. M., Bär, W., Kleihues, P., & Ohgaki, H. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.2.208 · Cited by 20
“There is convincing evidence that p53 mutations are not lost during glioma progression; they typically constitute early genetic events and have been shown to persist during malignant progression (3, 20, 24, 25), metastatic spread (26), and long-term culture in vitro (27).”
BackgroundSelf-citationUV-inducible base excision repair of oxidative damaged DNA in human cells
Kassam, S. N., & Rainbow, A. J. (2008) · Mutagenesis · doi:10.1093/mutage/gen054 · Cited by 19
“High p53 expression levels have been reported previously for LFS087 cells (39) and this is consistent with the accumulation of p53 in cells with mutant p53 (44).”
BackgroundKraus, A., Gross, M. W., Knuechel, R., Münkel, K., Neff, F., & Schlegel, J. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.93.5.0863 · Cited by 18
Molecular aspects of neuro-oncology
Santarius, T., Kirsch, M., Rossi, M. L., & Black, P. M. (1997) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(97)00025-5 · Cited by 18
Vogelbaum, M. A., Tong, J. X., Higashikubo, R., Gutmann, D. H., & Rich, K. M. (1998) · Journal of neurosurgery · doi:10.3171/jns.1998.88.1.0099 · Cited by 17
Amirlak, B., & Couldwell, W. T. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1023906316524 · Cited by 16
“Glioma cells with p53 mutations have increased levels of this protein (owing to increased half-life), which could be present in the cytoplasm [121].”
BackgroundPerspectives of Cellular and Molecular Neurosurgery
Westphal, M., & Black, P. M. (2004) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-2754-3 · Cited by 16
“Other viral gene therapies derived from the molecular target searches summarized in this volume are aimed at reconstituting the apoptotic pathways which in many gliomas are impaired through the already mentioned mutations of p53 gene [118,119] or the disruption of the RB-pathway by the less frequent mutations of the R…”
BackgroundSelf-citationClark, A. J., Chan, D. C., Chen, M. Y., Fillmore, H. L., dos Santos, W. G., Meter, T. E. V., Graf, M. R., & Broaddus, W. C. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9317-8 · Cited by 15
“mutations cause stabilization of the protein [37] (Fig.”
BackgroundPykett, M. J., Landers, J. E., & George, D. L. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005779406636 · Cited by 15
“Recently, it has been recognized that a number of human tumors exhibit elevated levels of an apparently wild-type p53 protein in the absence of p53 gene mutation, altered p53 mRNA expression, or viral infection [14–17].”
BackgroundComparative assessment of the functional p53 status in glioma cells.
Kim, E. L., Yoshizato, K., Kluwe, L., Meissner, H., Warnecke, G., Zapf, S., Westphal, M., Deppert, W., & Giese, A. (2005) · PubMed · Cited by 16
Self-citationChapter 8 Establishing Human Glioma-Derived Cell Lines
Westphal, M., & Meissner, H. (1998) · Methods in cell biology · doi:10.1016/s0091-679x(08)61576-9 · Cited by 14
Self-citationKhalid, M. H., Yagi, N., & Hiura, T. (1998) · Brain Tumor Pathology · doi:10.1007/bf02478889 · Cited by 15
Establishment and Characterization of a Human Glioblastoma Multiforme Cell Line
Bakır, A., Gezen, F., Yıldız, O., Ayhan, A., Kahraman, S., Kruse, C. A., Varella‐Garcia, M., Yıldız, F., & Kubar, A. (1998) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(97)00364-6 · Cited by 14
Molecular markers relating to malignant progression in Grade II astrocytoma
Yue, W.-Y., Yu, S.-H., Zhao, S., & Chen, Z.-P. (2008) · Journal of neurosurgery · doi:10.3171/2008.3.jns17459 · Cited by 13
Fischer, U., Kim, E. L., Keller, A., & Meese, E. U. (2017) · Oncotarget · doi:10.18632/oncotarget.15980 · Cited by 10
“Interestingly, G112 harbors a mutant TP53 (mut p53, 273H) as described previously [9-11].”
Evaluation of TNF-α/Bax Gene Therapy and Radiation against C6 Glioma Xenografts
Gridley, D. S., Timiryasova, T. M., Miller, G. M., Andres, M. L., Dutta-Roy, R., Bayeta, E. J. M., & Fodor, I. (2003) · Technology in Cancer Research & Treatment · doi:10.1177/153303460300200106 · Cited by 7
In vitro radiosensitization by pentoxifylline does not depend on p53 status
Akudugu, J., Serafin, A. M., & Böhm, L. (2013) · International Journal of Radiation Biology · doi:10.3109/09553002.2013.766771 · Cited by 4
“…G62, G44) and p53-mutant (G28, G60, G112) based on immunofl uorescence staining, direct DNA sequencing and temperature-gradient gel electrophoresis (Anker et al. 1993, Westphal and Meissner 1998). p53 mutation analyses were restricted to exons 5 to 8, and point mutations were identifi ed in exons…”
BackgroundMethodAccumulation of class I mutant p53 and apoptosis induced by carboplatin in a human glioma cell line
Hamada, Y., Mizoguchi, M., Suzuki, S. O., & Iwaki, T. (1998) · Brain Tumor Pathology · doi:10.1007/bf02478887 · Cited by 3
Ali‐Osman, F. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46861-1_11 · Cited by 2
Tumor Suppressor Gene Therapy for Brain Tumors
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., & Yung, W. K. A. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-478-8_12 · Cited by 2
A Cell Line–based Immunohistochemical p53 Expression Pattern Control Panel
Hussain, I., Howard, R. S., Syed, V., Allgäuer, M., Gong, H., Xing, D., & Andersen, J. D. (2018) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000537 · Cited by 1
Diffuse Low-Grade Astrocytomas: P53-Mediated Inhibition of Angiogenesis
Gaiser, T., & Siegelin, M. D. (2011) · Springer eBooks · doi:10.1007/978-94-007-2019-0_16
Methods of Determining Apoptosis in Neuro-Oncology
Ragel, B. T., Amirlak, B., Rao, G., & Couldwell, W. T. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-021-8_12
Grossman, R., Ram, Z., Vogelbaum, M. A., Chiocca, E. A., Westphal, M., Tonn, J., Kreth, F. W., & Thon, N. (2019) · Springer eBooks · doi:10.1007/978-3-030-04152-6_6
Self-citationWestphal, M., & Lamszus, K. (2010) · Springer eBooks · doi:10.1007/978-3-642-02874-8_2
Self-citationCaractérisation moléculaire des tumeurs cérébrales circonscrites de l'enfant
Padovani, L. (2013) · theses.fr (ABES) · doi:10.70675/4f3d78f1z0032z4f26za5d9z71257dec39f9
FGFR1 drives metabolic adaptation associated with temozolomide resistance in glioblastoma
Zarzuela, L., López-Cepero, I. G., Rattigan, K. M., Reina-Bando, A., Martín-Montalvo, J., Sierra-Párraga, J. M., Sánchez-Escabias, E., Morillo‐Huesca, M., Oltra, S. S., Ceballos-Chávez, M., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218565
“G123 cultures were maintained in DMEM medium supplemented with 10% FCS, 2 mM glutamine and 1% penicillin/streptomycin [42].”
Metadata
- Authors
- Anker, L., Ohgaki, H., Ludeke, B. I., Herrmann, H., Kleihues, P., & Westphal, M.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- University of Zurich (CH)
- Corresponding author
- Westphal, Manfred
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1993-12-02
- Volume
- 55
- Issue
- 6
- Pages
- 982-987
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2002666984
- Cited by
- 66
- References
- 34
- Citations by year
- 2026: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 3 · 2013: 4 · 2012: 1
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- p53, glioma cell lines, glioblastoma, TP53 mutation, p53 accumulation, tumor suppressor, loss of heterozygosity, malignant brain tumors
- MeSH terms
- Base Sequence, Chromosome Deletion, Codon, Exons, Female, Glioma, Humans, Male, Molecular Sequence Data, Precipitin Tests, Tumor Cells, Cultured, Blotting, Western, Polymerase Chain Reaction, Genes, p53, Tumor Suppressor Protein p53, Point Mutation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.